NCT03400332 is a Phase 1, PHASE2 clinical trial of BMS-986253 in Cancer, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT03400332?

NCT03400332 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT03400332?

Interventions in NCT03400332: BMS-986253, Nivolumab, Ipilimumab, Placebo.

What condition does NCT03400332 study?

NCT03400332 studies Cancer, Melanoma.

Is NCT03400332 still recruiting?

NCT03400332 is currently completed. Last updated 24 February 2026.

Are results published for NCT03400332?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-02-24 · How we verify

NCT03400332

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Completed Phase 1, PHASE2 Results posted Last updated 24 February 2026

What this trial tests

Phase 1, PHASE2 trial testing BMS-986253 in Cancer in 281 participants. Completed in 4 December 2025.

Timeline

12 February 2018

Primary endpoint
26 April 2024

4 December 2025

Quick facts

Lead sponsor	Bristol-Myers Squibb
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	281
Start date	12 February 2018
Primary completion	26 April 2024
Estimated completion	4 December 2025
Sites	72 locations across France, Italy, Belgium, Sweden, United Kingdom, Germany, Poland, Canada

Drugs / interventions tested

BMS-986253 — full drug profile →
Nivolumab (nivolumab) — full drug profile →
Ipilimumab — full drug profile →
Placebo

Conditions studied

Cancer — all drugs for Cancer →
Melanoma — all drugs for Melanoma →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Cancer or Melanoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants Experiencing Adverse Events (AEs) - Part 1 Primary · From first dose up to 100 days after last dose (up to 65 months)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events a

Group	Value	95% CI
Part 1: 600 Q4W	16
Part 1: 1200 Q4W	14
Part 1: 2400 Q4W	18
Part 1: 1200 Q2W	12
Part 1: 2400 Q2W	60
Part 1: 3600 Q2W	20
Part 1: 3600Q2W + Nivo + Ipi	15

Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1 Primary · From first dose up to 100 days after last dose (up to 65 months)

A serious adverse event is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event. This endpoint was prespecified in the protocol to include only participants in Part 1.

Group	Value	95% CI
Part 1: 600 Q4W	13
Part 1: 1200 Q4W	10
Part 1: 2400 Q4W	13
Part 1: 1200 Q2W	7
Part 1: 2400 Q2W	31
Part 1: 3600 Q2W	12
Part 1: 3600Q2W + Nivo + Ipi	9

Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1 Primary · From first dose up to 100 days after last dose (up to 65 months)

Dose-Limiting Toxicities (DLTs) are effects of a treatment that are serious enough to prevent an increase in dose of that treatment, as advised by the Dose Review Team. DLTs will be defined based on the incidence, intensity, and duration of AEs that are possibly related to study treatment. DLTs will include gastrointestinal, hepatic, hematologic, dermatologic, and other AEs. This endpoint was prespecified in the protocol to include only participants in Part 1.

Group	Value	95% CI
Part 1: 600 Q4W	0
Part 1: 1200 Q4W	0
Part 1: 2400 Q4W	0
Part 1: 1200 Q2W	0
Part 1: 2400 Q2W	0
Part 1: 3600 Q2W	0
Part 1: 3600Q2W + Nivo + Ipi	0

Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1 Primary · From first dose up to 100 days after last dose (up to 65 months)

Number of participants with any grade adverse events (AEs) leading to discontinuation of study treatment. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. This endpoint was prespecified in the protocol to include only participants in Part 1.

Group	Value	95% CI
Part 1: 600 Q4W	3
Part 1: 1200 Q4W	2
Part 1: 2400 Q4W	3
Part 1: 1200 Q2W	3
Part 1: 2400 Q2W	7
Part 1: 3600 Q2W	1
Part 1: 3600Q2W + Nivo + Ipi	3

Number of Participants Who Died - Part 1 Primary · From first dose up to 100 days after last dose (up to 65 months)

The number of participants who died due to any cause are summarized. This endpoint was prespecified in the protocol to include only participants in Part 1.

Group	Value	95% CI
Part 1: 600 Q4W	14
Part 1: 1200 Q4W	15
Part 1: 2400 Q4W	17
Part 1: 1200 Q2W	10
Part 1: 2400 Q2W	53
Part 1: 3600 Q2W	13
Part 1: 3600Q2W + Nivo + Ipi	8

Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 1 Primary · From first dose up to 30 days after last dose (up to 63 months)

Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Laboratory tests are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. This endpoint was prespecified in the protocol to include only participants in Part 1.

Hemoglobin - Grade 3

Group	Value	95% CI
Part 1: 600 Q4W	2
Part 1: 1200 Q4W	1
Part 1: 2400 Q4W	2
Part 1: 1200 Q2W	2
Part 1: 2400 Q2W	7
Part 1: 3600 Q2W	3
Part 1: 3600Q2W + Nivo + Ipi	3

Alanine aminotransferase - Grade 3

Group	Value	95% CI
Part 1: 600 Q4W	0
Part 1: 1200 Q4W	1
Part 1: 2400 Q4W	0
Part 1: 1200 Q2W	0
Part 1: 2400 Q2W	0
Part 1: 3600 Q2W	0
Part 1: 3600Q2W + Nivo + Ipi	2

Alkaline phosphatase - Grade 3

Group	Value	95% CI
Part 1: 600 Q4W	0
Part 1: 1200 Q4W	0
Part 1: 2400 Q4W	2
Part 1: 1200 Q2W	0
Part 1: 2400 Q2W	2
Part 1: 3600 Q2W	3
Part 1: 3600Q2W + Nivo + Ipi	2

Aspartate aminotransferase - Grade 3

Group	Value	95% CI
Part 1: 600 Q4W	0
Part 1: 1200 Q4W	1
Part 1: 2400 Q4W	0
Part 1: 1200 Q2W	0
Part 1: 2400 Q2W	0
Part 1: 3600 Q2W	2
Part 1: 3600Q2W + Nivo + Ipi	1

Phosphate - Grade 3

Group	Value	95% CI
Part 1: 600 Q4W	0
Part 1: 1200 Q4W	1
Part 1: 2400 Q4W	2
Part 1: 1200 Q2W	0
Part 1: 2400 Q2W	3
Part 1: 3600 Q2W	1
Part 1: 3600Q2W + Nivo + Ipi	0

Sodium - Grade 3

Group	Value	95% CI
Part 1: 600 Q4W	0
Part 1: 1200 Q4W	2
Part 1: 2400 Q4W	1
Part 1: 1200 Q2W	0
Part 1: 2400 Q2W	5
Part 1: 3600 Q2W	1
Part 1: 3600Q2W + Nivo + Ipi	2

Lipase - Grade 3

Group	Value	95% CI
Part 1: 600 Q4W	1
Part 1: 1200 Q4W	1
Part 1: 2400 Q4W	2
Part 1: 1200 Q2W	1
Part 1: 2400 Q2W	3
Part 1: 3600 Q2W	0
Part 1: 3600Q2W + Nivo + Ipi	2

Lipase - Grade 4

Group	Value	95% CI
Part 1: 600 Q4W	0
Part 1: 1200 Q4W	0
Part 1: 2400 Q4W	0
Part 1: 1200 Q2W	1
Part 1: 2400 Q2W	2
Part 1: 3600 Q2W	0
Part 1: 3600Q2W + Nivo + Ipi	2

Objective Response Rate (ORR) - Part 1 Secondary · From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)

Objective Response Rate per investigator is the percentage of participants who have a confirmed complete or partial best overall response (BOR) among participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before

Group	Value	95% CI
Part 1: 600 Q4W	6.3	0.2 – 30.2
Part 1: 1200 Q4W	6.7	0.2 – 31.9
Part 1: 2400 Q4W	16.7	3.6 – 41.4
Part 1: 1200 Q2W	0	0.0 – 26.5
Part 1: 2400 Q2W	3.2	0.4 – 11.0
Part 1: 3600 Q2W	10.0	1.2 – 31.7
Part 1: 3600Q2W + Nivo + Ipi	13.3	1.7 – 40.5

Duration of Response (DOR) - Part 1 Secondary · From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 74 months)

DOR for a participant with a best overall response (BOR) of CR or PR is defined as the date of first response up to the date of the first objectively documented tumor progression by the investigator per RECIST v1.1 or death, whichever occurs first. Analysis computed using Kaplan-Meier method. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to =\< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameter

Group	Value	95% CI
Part 1: 600 Q4W	3.7	3.7 – 3.7
Part 1: 1200 Q4W	28.9	28.9 – 28.9
Part 1: 2400 Q4W	44.6	8.4 – 44.6
Part 1: 2400 Q2W	21.09	4.0 – 21.1
Part 1: 3600 Q2W	3.4	3.4 – 3.4
Part 1: 3600Q2W + Nivo + Ipi	NA	3.7 – 24.0

Maximum Concentration (Cmax) - Part 1 Secondary · Cycle 1 Day 1

Cmax is the maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and before the administration of a second dose. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Group	Value	95% CI
Part 1: 600 Q4W	142.91	± 52.1
Part 1: 1200 Q4W	352.12	± 62.7
Part 1: 2400 Q4W	779.90	± 43.1
Part 1: 1200 Q2W	325.67	± 24.0
Part 1: 2400 Q2W	919.44	± 32.8
Part 1: 3600 Q2W	1227.67	± 23.3
Part 1: 3600Q2W + Nivo + Ipi	999.60	± 29.4

AUC(0-T)-Area Under Curve From Time Zero up to Last Quantifiable Concentration - Part 1 Secondary · 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Cycle 1 Day 1

AUC (0-T) represents the observed exposure to a drug (area under the concentration curve) from first exposure until the last quantifiable concentration. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Group	Value	95% CI
Part 1: 600 Q4W	19594.22	± 52.7
Part 1: 1200 Q4W	44821.39	± 44.5
Part 1: 2400 Q4W	105171.46	± 29.7
Part 1: 1200 Q2W	42835.41	± 28.1
Part 1: 2400 Q2W	112123.35	± 34.2
Part 1: 3600 Q2W	148321.77	± 32.0
Part 1: 3600Q2W + Nivo + Ipi	118041.10	± 40.3

AUC(TAU)-Area Under Curve in 1 Dosing Interval - Part 1 Secondary · Cycle 1 Day 1

Area under the concentration-time curve in 1 dosing interval. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group (1 cycle=42 days)

Group	Value	95% CI
Part 1: 600 Q4W	21301.74	± 49.5
Part 1: 1200 Q4W	48664.06	± 42.9
Part 1: 2400 Q4W	106916.11	± 27.3
Part 1: 1200 Q2W	43844.97	± 24.8
Part 1: 2400 Q2W	113969.47	± 30.8
Part 1: 3600 Q2W	153791.84	± 27.9
Part 1: 3600Q2W + Nivo + Ipi	137809.44	± 29.5

Observed Serum Concentration at the End of a Dosing Interval (Ctau) - Part 1 Secondary · Cycle 1 Day 1

BMS-986253 observed serum concentration at the end of a dosing interval (Ctau). Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint. 1 cycle=28 days for all Arms/Groups except Cycles 1 and 2 (1 cycle=42 days) in "Part 1: 3600Q2W + Nivo + Ipi" Arm/Group

Group	Value	95% CI
Part 1: 600 Q4W	6.81	± 173.8
Part 1: 1200 Q4W	14.92	± 144.4
Part 1: 2400 Q4W	23.68	± 692.4
Part 1: 1200 Q2W	55.82	± 53.0
Part 1: 2400 Q2W	141.89	± 42.6
Part 1: 3600 Q2W	181.84	± 46.3
Part 1: 3600Q2W + Nivo + Ipi	175.29	± 46.6

Adverse events — posted to ClinicalTrials.gov

Time frame: Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 74 months). SAEs and Other AEs were assessed from first dose to 100 days post the last dose (up to approximately 65 months).. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part 1: 600 Q4W

Serious: 13/16 (81%)

Deaths: 14/16

Part 1: 1200 Q4W

Serious: 10/15 (67%)

Deaths: 15/15

Part 1: 2400 Q4W

Serious: 13/18 (72%)

Deaths: 17/18

Part 1: 1200 Q2W

Serious: 7/12 (58%)

Deaths: 10/12

Part 1: 2400 Q2W

Serious: 31/63 (49%)

Deaths: 53/63

Part 1: 3600 Q2W

Serious: 12/20 (60%)

Deaths: 13/20

Part 1: 3600Q2W + Nivo + Ipi

Serious: 9/15 (60%)

Deaths: 8/15

Part 2 Arm A: BMS+Nivo+Ipi

Serious: 44/62 (71%)

Deaths: 30/62

Part 2 Arm B: Placebo+Nivo+Ipi

Serious: 42/57 (74%)

Deaths: 17/60

Serious adverse events (146 terms)

Reaction	System	Part 1: 600 Q4W	Part 1: 1200 Q4W	Part 1: 2400 Q4W	Part 1: 1200 Q2W	Part 1: 2400 Q2W	Part 1: 3600 Q2W	Part 1: 3600Q2W + Nivo + Ipi	Part 2 Arm A: BMS+Nivo+Ipi	Part 2 Arm B: Placebo+Nivo…
Malignant neoplasm progression	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Death	General disorders	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—
Haemophagocytic lymphohistiocytosis	Immune system disorders	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—
General physical health deterioration	General disorders	—	—	—	—	—	—	—	—	—
Cholecystitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Haemoptysis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Hypoxia	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—
Pancytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—
Acute coronary syndrome	Cardiac disorders	—	—	—	—	—	—	—	—	—

Other adverse events (267 terms — click to expand)

Reaction	System	Part 1: 600 Q4W	Part 1: 1200 Q4W	Part 1: 2400 Q4W	Part 1: 1200 Q2W	Part 1: 2400 Q2W	Part 1: 3600 Q2W	Part 1: 3600Q2W + Nivo + Ipi	Part 2 Arm A: BMS+Nivo+Ipi	Part 2 Arm B: Placebo+Nivo…
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—	—	—	—	—	—	—
Lipase increased	Investigations	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—
Blood lactate dehydrogenase increased	Investigations	—	—	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—
Lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—
Amylase increased	Investigations	—	—	—	—	—	—	—	—	—
Protein total decreased	Investigations	—	—	—	—	—	—	—	—	—
Hypocalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—
Blood albumin decreased	Investigations	—	—	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Colitis	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Malignant neoplasm progression, Colitis, Pneumonia, Hyponatraemia, Diarrhoea, Death, Dyspnoea, Pyrexia.

Data from ClinicalTrials.gov NCT03400332 adverse events section.

Sponsor's own description

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cytokines in clinical cancer immunotherapy.
Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, et al · · 2019 · cited 834× · PMID 30413827 · DOI 10.1038/s41416-018-0328-y
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
Li K, Shi H, Zhang B, Ou X, et al · · 2021 · cited 687× · PMID 34620838 · DOI 10.1038/s41392-021-00670-9
Interleukins in cancer: from biology to therapy.
Briukhovetska D, Dörr J, Endres S, Libby P, et al · · 2021 · cited 587× · PMID 34083781 · DOI 10.1038/s41568-021-00363-z
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.
Schalper KA, Carleton M, Zhou M, Chen T, et al · · 2020 · cited 429× · PMID 32405062 · DOI 10.1038/s41591-020-0856-x
Next generation of immune checkpoint inhibitors and beyond.
Marin-Acevedo JA, Kimbrough EO, Lou Y. · · 2021 · cited 401× · PMID 33741032 · DOI 10.1186/s13045-021-01056-8
The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.
Cambier S, Gouwy M, Proost P. · · 2023 · cited 387× · PMID 36725964 · DOI 10.1038/s41423-023-00974-6
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y, Tang F, Wei YQ, Wei XW. · · 2022 · cited 386× · PMID 35585567 · DOI 10.1186/s13045-022-01282-8
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression.
Fousek K, Horn LA, Palena C. · · 2021 · cited 278× · PMID 32980444 · DOI 10.1016/j.pharmthera.2020.107692

Verify or expand the search:

Other trials of BMS-986253

Trials testing the same drug.

NCT05148234 — BMS-986253 in Myelodysplastic Syndromes · Phase 1, PHASE2 · terminated
NCT04572451 — Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanom · Phase 1 · recruiting
NCT04347226 — Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 · Phase 2 · terminated
NCT04123379 — Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carci · Phase 2 · active not recruiting
NCT03026140 — Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer · Phase 2 · recruiting

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03400332 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 24 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03400332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing